Skip to main content

Table 1 Demographic and clinical characteristics of the study population

From: SerumĀ free thiols predict cardiovascular events and all-cause mortality in the general population: a prospective cohort study

Ā 

Total, Nā€‰=ā€‰5955

T1, Nā€‰=ā€‰1985

T2, Nā€‰=ā€‰1985

T3, Nā€‰=ā€‰1985

P value

SerumĀ free thiol (Ī¼mol/g) levels (adjusted for protein)

5.05 (Ā±ā€‰1.02) Ī¼mol/g

<ā€‰4.65ā€‰Ī¼mol/g

4.65ā€“5.46ā€‰Ī¼mol/g

>ā€‰5.46ā€‰Ī¼mol/g

Ā 

Age (years)

51.6 (43.3ā€“61.7)

57.6 (47.8ā€“66.6)

51.1 (43.4ā€“59.8)

47.7 (41.1ā€“55.3)

<ā€‰0.001

Female, n (%)

3038 (51.0%)

1084 (54.6%)

1013 (51.0%)

941 (47.4%)

<ā€‰0.001

Blood pressure

ā€ƒSBP (mmHg)

126 (Ā±ā€‰19)

129 (Ā±ā€‰20)

125 (Ā±ā€‰18)

123 (Ā±ā€‰17)

<ā€‰0.001

ā€ƒDBP (mmHg)

73 (Ā±ā€‰9)

74 (Ā±ā€‰9)

73 (Ā±ā€‰9)

73 (Ā±ā€‰9)

<ā€‰0.001

ā€ƒHeart rate (bpm)

68 (Ā±ā€‰10)

69 (Ā±ā€‰11)

69 (Ā±ā€‰10)

68 (Ā±ā€‰10)

0.44

Obesity variables

ā€ƒBMI (kg/m2)

26.0 (23.6ā€“28.9)

26.8 (24.3ā€“29.9)

26.0 (23.6ā€“28.7)

25.3 (23.0ā€“28.0)

<ā€‰0.001

ā€ƒWaist circumference (cm)

91.0 (82.0ā€“100.0)

94.0 (85.0ā€“102.0)

91.0 (82.0ā€“100.0)

89.0 (81.0ā€“98.0)

<ā€‰0.001

Smoking, n (%)

Ā Ā Ā Ā 

<ā€‰0.001

ā€ƒNever, n (%)

1757 (29.5%)

583 (29.4%)

578 (29.1%)

596 (30.0%)

Ā 

ā€ƒCurrent, n (%)

1655 (27.8%)

494 (24.9%)

538 (27.1%)

623 (31.4%)

Ā 

ā€ƒFormer, n (%)

2472 (41.5%)

887 (44.7%)

848 (42.7%)

737 (37.1%)

Ā 

History of cardiovascular disease, n (%)

217 (3.6%)

100 (5.0%)

69 (3.5%)

48 (2.4%)

<ā€‰0.001

Diabetes, n (%)

144 (2.4%)

76 (3.8%)

34 (1.7%)

34 (1.7%)

<ā€‰0.001

Medication, n (%)

ā€ƒAntihypertensive drugs, n (%)

1037 (17.4%)

481 (24.2%)

307 (15.5%)

249 (12.5%)

<ā€‰0.001

ā€ƒLipid-lowering drugs, n (%)

371 (6.2%)

155 (7.8%)

126 (6.3%)

90 (4.5%)

<ā€‰0.001

ā€ƒAntidiabetic drugs, n (%)

78 (1.3%)

40 (2.0%)

19 (1.0%)

19 (1.0%)

0.006

Laboratory measurements

ā€ƒTotal cholesterol (mmol/L)

5.5 (Ā±ā€‰1.0)

5.5 (Ā±ā€‰1.0)

5.5 (Ā±ā€‰1.0)

5.4 (Ā±ā€‰1.1)

<ā€‰0.001

ā€ƒHDL (mmol/L)

1.2 (1.0ā€“1.5)

1.2 (1.1ā€“1.5)

1.2 (1.0ā€“1.4)

1.2 (1.0ā€“1.4)

0.68

ā€ƒLDL (mmol/L)

3.4 (2.7ā€“4.2)

3.5 (2.8ā€“4.2)

3.3 (2.7ā€“4.1)

3.3 (2.6ā€“4.1)

0.20

ā€ƒTriglycerides (mmol/L)

1.1 (0.8ā€“1.6)

1.1 (0.8ā€“1.6)

1.1 (0.8ā€“1.6)

1.0 (0.8ā€“1.6)

0.001

ā€ƒhsCRP (mg/L)

1.3 (0.6ā€“2.9)

1.6 (0.8ā€“3.9)

1.3 (0.6ā€“2.8)

1.0 (0.5ā€“2.3)

<ā€‰0.001

ā€ƒFasting glucose (mmol/L)

4.7 (4.4ā€“5.2)

4.8 (4.5ā€“5.3)

4.7 (4.4ā€“5.2)

4.7 (4.4ā€“5.2)

<ā€‰0.001

ā€ƒeGFR (mL/min/1.73Ā m2)

94.5 (82.2ā€“104.7)

86.5 (74.7ā€“99.0)

95.0 (83.9ā€“14.0)

99.8 (90.1ā€“108.2)

<ā€‰0.001

ā€ƒAlbuminuria (mg/L)

8.5 (6.0ā€“15.0)

9.3 (6.2ā€“19.0)

8.4 (6.0ā€“14.0)

8.1 (5.95ā€“13.1)

<ā€‰0.001

CV events, n (%)

402 (6.8%)

184 (9.3%)

127 (6.4%)

91 (4.6%)

<ā€‰0.001

Mortality, n (%)

316 (5.3%)

171 (8.6%)

85 (4.3%)

60 (3.0%)

<ā€‰0.001

  1. Data are presented as meanā€‰Ā±ā€‰SD, proportions n with corresponding percentages (%) or median (IQR)
  2. P values in bold indicate statistical significance
  3. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, hsCRP high-sensitive C-reactive protein, eGFR estimated glomerular filtration rate, CV cardiovascular